SCO1 and fatty liver disease: Lastly, patients with SCO1 mutations (impacting complex IV assembly) display hepatic steatosis and elevated acyl-carnitines (Valnot et al., 2000; Stiburek et al., 2009), suggesting a clinical overlap between mitochondrial ETC inhibition and ETF complex deficiency.